Abstract 797P
Background
The available prognostic models of OS for pts with metastatic UC were derived from clinical trial populations of cisplatin-treated pts only. We aimed to develop a new model based on ‘real world’ pts.
Methods
Individual pt-level data from 29 centers was collected. Pts had to be treated for metastatic UC at the participating sites between 01/2006 and 01/2011. Selection criteria included metastatic UC, and first-line cisplatin- or carboplatin-based chemotherapy. The overall sample was randomly split into a development and a validation cohort. Generalized Boosted Regression Modeling was used first to exclude variables not associated with OS. Backward variable selection was then undertaken. Platinum-type was incorporated in the analysis as a stratification factor. Two nomograms were built to estimate OS probability, the first based on baseline factors and the second incorporating objective response (OR). The performance of the present nomogram and that of the other available models was assessed for accuracy (Brier score), calibration (Hosmer-Lemeshow test), and discrimination (Harrell c-index).
Results
1,020 pts were analyzed (development: 687; validation: 333). In the platinum-stratified Cox model, significant variables for OS were: performance status (p
Conclusions
We developed and validated two nomograms that accounted for novel prognostic factors and can be used before and after completion of chemotherapy, respectively. These two nomograms may be suitable tools to enhance patient stratification and inform pts in the clinic.
Clinical trial identification
None
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori
Funding
Fondazione IRCCS Istituto Nazionale dei Tumori
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract